Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBT (2022 - 2025)

Historic EBT for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' EBT rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year increase of 2598.24%. This contributed to the annual value of -$287.1 million for FY2024, which is 2050.25% down from last year.
  • Per Axsome Therapeutics' latest filing, its EBT stood at -$47.2 million for Q3 2025, which was up 2689.24% from -$48.9 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' EBT peaked at -$8.6 million during Q1 2023, and registered a low of -$99.0 million during Q4 2023.
  • For the 4-year period, Axsome Therapeutics' EBT averaged around -$57.9 million, with its median value being -$61.2 million (2022).
  • In the last 5 years, Axsome Therapeutics' EBT surged by 7820.45% in 2023 and then plummeted by 69135.22% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' EBT stood at -$61.2 million in 2022, then tumbled by 61.62% to -$99.0 million in 2023, then grew by 24.4% to -$74.8 million in 2024, then skyrocketed by 36.88% to -$47.2 million in 2025.
  • Its EBT was -$47.2 million in Q3 2025, compared to -$48.9 million in Q2 2025 and -$59.4 million in Q1 2025.